Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma
- Provide treatment with antineoplastons A10 and AS2-1 to patients with stage IV
- Describe the response to, tolerance to, and side effects of this regimen in these
OUTLINE: Patients receive gradually escalating doses of antineoplaston A10 and
antineoplaston AS2-1 IV six times per day until the maximum dose is reached.
Treatment continues for at least 3 months in the absence of disease progression or
unacceptable toxicity. After 3 months, patients with stable or responding disease may
continue treatment. Patients achieving complete response (CR) continue treatment for at
least 8 months beyond CR.
Patients are followed every 2 months for 1 year and then every 3 months for the second year.
PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study.
Primary Purpose: Treatment
Response rate based on tumor measurements taken at 12 weeks
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
|Burzynski Clinic||Houston, Texas 77055-6330|